Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Sinovac Biotech Ltd is a China-based biopharmaceutical company. The company primarily focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. The company also provides services for diseases control and prevention, collaborating with the Chinese governments at the national, state and local levels. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets.
Beijing, 102200, Antigua and Barbuda